First humans receive experimental arthritis drug in groundbreaking safety trial
Disease control
Recruiting now
This is the first time researchers are testing a new drug called KT501 in people with rheumatoid arthritis. The main goal is to check if it's safe and see how the body processes it. About 24 adults with active RA will receive one injection and be monitored for 12 weeks, with some…
Phase: PHASE1 • Sponsor: Kali Therapeutics, Inc. • Aim: Disease control
Last updated Mar 23, 2026 15:16 UTC